Introduction
Atherosclerosis is characterized by the accumulation of plaques within arterial walls. While plaque size is a concern, the primary clinical danger is plaque vulnerability—the likelihood that a plaque will rupture and cause a heart attack or stroke. A critical factor in this instability is the pathological proliferation of the adventitial vasa vasorum (VV). These microscopic vessels, which normally nourish the outer arterial layers, can grow uncontrollably into the plaque, delivering inflammatory cells and promoting intraplaque hemorrhage.
Ginsenoside Rb1, a major active component of ginseng, has long been recognized for its cardiovascular benefits. This study investigates whether Rb1 can stabilize atherosclerotic plaques by targeting the vasa vasorum and the molecular pathways governing their growth, specifically focusing on the microRNA-33 (miR-33) and Pigment Epithelium-Derived Factor (PEDF) axis.
Methods
The researchers employed an Apolipoprotein E-deficient (ApoE−/−) mouse model, a standard for atherosclerosis research.
- Plaque Induction: Mice were fed a high-fat diet (HFD) for 20 weeks to establish significant atherosclerotic lesions.
- Treatment Groups: Following induction, mice received either a control vehicle or Ginsenoside Rb1 (50 mg/kg/day) via intraperitoneal injection for 4 weeks.
- Mechanistic Validation: To test the role of miR-33, a third group received Rb1 treatment along with a lentivirus to overexpress miR-33, effectively challenging the drug's mechanism.
- Analysis: Plaque burden was quantified using Oil Red O staining of the aorta. Plaque composition and stability were assessed via immunohistochemistry for inflammatory markers (MOMA-2), smooth muscle cells, and collagen. The vasa vasorum were visualized using tomato lectin perfusion.
Key Results
The study demonstrated that Ginsenoside Rb1 significantly impacts both plaque size and stability.
Plaque Reduction and Stabilization
Rb1 treatment led to a marked decrease in the total plaque area within the aorta. More importantly, it improved the vulnerability index—a ratio measuring lipids and macrophages against smooth muscle cells and collagen. Rb1-treated plaques were more fibrous and less inflammatory, indicating higher stability.
Inhibition of Vasa Vasorum and Inflammation
A key finding was the significant reduction in adventitial vasa vasorum proliferation in the Rb1 group. By suppressing these "highways" for inflammatory infiltration, Rb1 also lowered the levels of pro-inflammatory cytokines such as IL-1β, IL-6, and TNF-α within the arterial wall.
The miR-33/PEDF Pathway
The molecular mechanism was traced to a specific genetic toggle. Rb1 treatment downregulated miR-33, which in turn increased the expression of PEDF, a potent anti-angiogenic protein. When miR-33 was artificially overexpressed, the beneficial effects of Rb1—including plaque stabilization and VV suppression—were largely abolished, confirming that the Rb1 -> miR-33 -> PEDF pathway is central to its therapeutic action.
Discussion and Conclusion
This research identifies Ginsenoside Rb1 as a potent regulator of plaque stability. By modulating the miR-33/PEDF axis, Rb1 inhibits the pathological growth of the vasa vasorum and reduces vascular inflammation.
While these results in ApoE−/− mice are promising, limitations remain. Mouse plaques do not perfectly replicate the spontaneous rupture seen in humans. Furthermore, the study used intraperitoneal injections; future work must evaluate the efficacy and bioavailability of Rb1 through oral administration to determine its potential as a long-term clinical therapy for human atherosclerosis. Nevertheless, the study provides a clear mechanistic basis for the anti-atherosclerotic properties of ginseng components.
Summary updated